Remove 2026 Remove Compounding Remove Pharmaceutical Companies
article thumbnail

Connected customer data: a golden opportunity for pharma marketers

pharmaphorum

Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. billion by 2026, according to research by the Business Research Company. Capturing market share.

article thumbnail

Orphan drugs’ financial success raises questions

pharmaphorum

In 1983, the US Congress passed the Orphan Drug Act to encourage more pharmaceutical companies to engage in R&D to develop treatments for rare diseases through the offering of financial incentives. By 2026, the report predicts that each of the top 10 selling orphan drugs will earn between $3 billion and $13 billion.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Cloud Computing for Pharma: The Road to Digital Transformation 

Viseven

By the end of 2026, the company will be able to analyze two million genomes. Life sciences companies can adopt third-party software-as-a-service (SaaS) solutions for drug discovery or build custom tools in collaboration with a cloud provider. It is no surprise that the global market is growing at a compound annual rate of 20%.

article thumbnail

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

Pharmaceutical Technology

billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. There are multiple drugs in the pipeline, predominantly me-too and biosimilar therapies, with a significant number developed in the emerging markets of India and China by domestic pharmaceutical companies for their own rapidly growing markets.